Plasma lipidomic profiling and risk of type 2 diabetes in the PREDIMED trial
Mostra el registre complet Registre parcial de l'ítem
- dc.contributor.author Razquin, Cristina
- dc.contributor.author Fitó Colomer, Montserrat
- dc.contributor.author Martinez-Gonzalez, Miguel A.
- dc.date.accessioned 2019-12-03T07:56:31Z
- dc.date.available 2019-12-03T07:56:31Z
- dc.date.issued 2018
- dc.description.abstract OBJECTIVE: Specific lipid molecular changes leading to type 2 diabetes (T2D) are largely unknown. We assessed lipidome factors associated with future occurrence of T2D in a population at high cardiovascular risk. RESEARCH DESIGN AND METHODS: We conducted a case-cohort study nested within the PREDIMED trial, with 250 incident T2D cases diagnosed during 3.8 years of median follow-up, and a random sample of 692 participants (639 noncases and 53 overlapping cases) without T2D at baseline. We repeatedly measured 207 plasma known lipid metabolites at baseline and after 1 year of follow-up. We built combined factors of lipid species using principal component analysis and assessed the association between these lipid factors (or their 1-year changes) and T2D incidence. RESULTS: Baseline lysophosphatidylcholines and lysophosphatidylethanolamines (lysophospholipids [LPs]), phosphatidylcholine-plasmalogens (PC-PLs), sphingomyelins (SMs), and cholesterol esters (CEs) were inversely associated with risk of T2D (multivariable-adjusted P for linear trend ≤0.001 for all). Baseline triacylglycerols (TAGs), diacylglycerols (DAGs), and phosphatidylethanolamines (PEs) were positively associated with T2D risk (multivariable-adjusted P for linear trend <0.001 for all). One-year changes in these lipids showed associations in similar directions but were not significant after adjustment for baseline levels. TAGs with odd-chain fatty acids showed inverse associations with T2D after adjusting for total TAGs. CONCLUSIONS: Two plasma lipid profiles made up of different lipid classes were found to be associated with T2D in participants at high cardiovascular risk. A profile including LPs, PC-PLs, SMs, and CEs was associated with lower T2D risk. Another profile composed of TAGs, DAGs, and PEs was associated with higher T2D risk.
- dc.format.mimetype application/pdf
- dc.identifier.citation Razquin C, Toledo E, Clish CB, Ruiz-Canela M, Dennis C, Corella D. et al. Plasma lipidomic profiling and risk of type 2 diabetes in the PREDIMED trial. Diabetes Care. 2018 Dec;41(12):2617-2624. DOI 10.2337/dc18-0840
- dc.identifier.doi http://dx.doi.org/10.2337/dc18-0840
- dc.identifier.issn 0149-5992
- dc.identifier.uri http://hdl.handle.net/10230/43055
- dc.language.iso eng
- dc.publisher American Diabetes Association
- dc.rights © American Diabetes Association. This is an author-created, uncopyedited electronic version of an article accepted for publication in Diabetes Care. The American Diabetes Association (ADA), publisher of Diabetes Care, is not responsible for any errors or omissions in this version of the manuscript or any version derived from it by third parties. The definitive publisher-authenticated version will be available in a future issue of Diabetes in print and online at http://diabetes.diabetesjournals.org.
- dc.rights.accessRights info:eu-repo/semantics/openAccess
- dc.subject.other Plasma sanguini
- dc.subject.other Diabetis
- dc.title Plasma lipidomic profiling and risk of type 2 diabetes in the PREDIMED trial
- dc.type info:eu-repo/semantics/article
- dc.type.version info:eu-repo/semantics/acceptedVersion